Phase 2a randomized, placebo-controlled study of anti–IL-33 in peanut allergy

BACKGROUNDIL-33, found in high levels in participants with allergic disorders, is thought to mediate allergic reactions. Etokimab, an anti-IL-33 biologic, has previously demonstrated a good safety profile and favorable pharmacodynamic properties in many clinical studies.METHODSIn this 6-week placebo...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	JCI insight Jg. 4; H. 22
Hauptverfasser:	Chinthrajah, Sharon, Cao, Shu, Liu, Cherie, Lyu, Shu-Chen, Sindher, Sayantani B., Long, Andrew, Sampath, Vanitha, Petroni, Daniel, Londei, Marco, Nadeau, Kari C.
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States American Society for Clinical Investigation 14.11.2019
Schlagworte:	Adolescent Adult Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - adverse effects Antibodies, Monoclonal - pharmacology Antibodies, Monoclonal - therapeutic use Cells, Cultured Clinical Medicine Cytokines - metabolism Double-Blind Method Female Humans Interleukin-33 - antagonists & inhibitors Male Middle Aged Peanut Hypersensitivity - drug therapy Peanut Hypersensitivity - immunology Placebos T-Lymphocytes - drug effects T-Lymphocytes - metabolism Young Adult Allergy Clinical Trials Immunology
ISSN:	2379-3708, 2379-3708
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!